What is the name of the experimental pill, and how did it impact survival time for patients with metastatic pancreatic cancer that had stopped responding to prior treatment?

The experimental pill is called daraxonrasib. In a study of 500 patients with metastatic pancreatic cancer that had quit responding to prior treatment, those taking daraxonrasib lived for a median of 13.2 months compared with 6.7 months for those receiving chemotherapy — nearly doubling median survival time.

Why is daraxonrasib considered a significant advance in pancreatic cancer treatment, according to the researchers involved?

Daraxonrasib is considered a significant advance because it is the first drug to show a substantial survival advantage over chemotherapy for previously treated metastatic pancreatic cancer; it targets a mutated protein that fuels tumor growth in more than 90% of cases — a target that had eluded treatment for decades — and it demonstrated fewer severe side effects, longer treatment duration, tumor shrinkage, less pain, and improved quality of life.

Experimental Pill Promises New Hope for Deadly Pancreatic Cancer

Jun 1, 2026

Revolution Medicines' experimental drug daraxonrasib nearly doubled survival time for advanced pancreatic cancer patients compared to chemotherapy. The FDA plans to expedite review as researchers hail it a potential new standard of care.

apnews

2026-06-01

Morning Bid: AI and 1984

2026-06-01

Experimental Pill Promises New Hope for Deadly Pancreatic Cancer

2026-08-26

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

Experimental Pill Promises New Hope for Deadly Pancreatic Cancer

FAQ